86P - Can concurrent chemo-radiation be delayed by induction chemotherapy in the curative treatment of stage III non-small cell lung carcinoma? A pooled a...

Date 17 April 2015
Event ELCC 2015
Session Poster lunch
Topics Anti-Cancer Agents & Biologic Therapy
Non-Small-Cell Lung Cancer, Locally Advanced
Surgery and/or Radiotherapy of Cancer
Presenter Catherine Guilbault
Citation Annals of Oncology (2015) 26 (suppl_1): 24-28. 10.1093/annonc/mdv049
Authors C. Guilbault1, A. Garant2, M. Almajed2, S. Faria2, S. Owen2, M. Duclos2, L. Ofiara2, J. Gruber2, V. Hirsh2, N. Kopek2
  • 1Oncology, McGill University, H3T 1E2 - Montreal/CA
  • 2Oncology, McGill University, Montreal/CA



Standard treatment for inoperable stage 3 NSCLC is concurrent chemo-radiation (CRT). In busy centers such as ours, a regimen of induction chemotherapy followed by CRT was developed as radiation treatment often could not be started promptly. In the induction phase, carboplatin (C) and gemcitabine (G) were given. In the CRT phase, low-dose paclitaxel (P) and G were used for their known radio-sensitizing properties. This approach was tested in a phase II protocol between 2003 and 2004 and continues to be routinely used at the McGill University Health Centre (MUHC). We report the long term outcomes with this regimen based on a pooled analysis of both protocol and non-protocol patients.


Forty-one stage 3 NSCLC patients were treated on protocol between January 2003, and November 2004. The outcomes and toxicity data of an additional 101 stage 3 NSCLC patients treated off-protocol with the same regimen between December 2004 and August 2013 at the MUHC were retrieved, giving a total of 142 patients: 80 males, 62 females, median age 64 (35-83), stage 3A (83 pts) or 3B (59 pts). Patients received 2 cycles of C AUC = 5 IV on day 1 and G 1000 mg/m2 IV on days 1 and 8 every 3 weeks x 2, followed on day 50 by CRT, 60Gy/30 over 6 weeks, concomitantly with P 50 mg/m2 IV and G 100 mg/m2 IV on days 1 and 8 every three weeks x 2 cycles.


The median overall survival was 23 months. With a median follow-up of 19 months, the 3, 4 and 5 year overall survival was 37% (38 pts remaining), 27% (21 pts), and 23% (15 pts) respectively. The median and 5 year progression-free survival rates were 11 months and 21% respectively. Rates of acute grade ≥ 3 hematological, esophageal and respiratory toxicity were, respectively, 20%, 8% and 7%. Forty-eight patients received further lines of chemotherapy.


The results of the present analysis based on 142 stage 3 NSCLC patients treated with this novel induction chemotherapy approach affirm its favourable toxicity profile without apparent compromise in clinical outcomes. Indeed, although the development of this regimen was motivated by delays to prompt commencement of CRT, the observed outcomes do compare favourably with those associated with immediate concurrent CRT regimens.


All authors have declared no conflicts of interest.